Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

IGM Biosciences stock

IGMS
US4495851085
A2PPQK

Price

14.50
Today +/-
-1.84
Today %
-13.14 %
P

IGM Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IGM Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IGM Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IGM Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IGM Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IGM Biosciences Stock Price History

DateIGM Biosciences Price
10/1/202414.50 undefined
9/30/202416.54 undefined
9/27/202417.00 undefined
9/26/202415.86 undefined
9/25/202416.41 undefined
9/24/202416.89 undefined
9/23/202415.99 undefined
9/20/202416.16 undefined
9/19/202417.23 undefined
9/18/202416.65 undefined
9/17/202417.68 undefined
9/16/202415.84 undefined
9/13/202412.30 undefined
9/12/202411.39 undefined
9/11/202411.74 undefined
9/10/202411.27 undefined
9/9/202410.27 undefined
9/6/20249.31 undefined
9/5/202410.25 undefined
9/4/202410.40 undefined
9/3/20249.86 undefined

IGM Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IGM Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IGM Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IGM Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IGM Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IGM Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IGM Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IGM Biosciences’s growth potential.

IGM Biosciences Revenue, EBIT and net profit per share

DateIGM Biosciences RevenueIGM Biosciences EBITIGM Biosciences Net Income
2029e555.47 M undefined0 undefined-99.84 M undefined
2028e359.36 M undefined-41.89 M undefined-160.95 M undefined
2027e224.36 M undefined-133.76 M undefined-162.16 M undefined
2026e45.52 M undefined-243.61 M undefined-152.93 M undefined
2025e8.98 M undefined-241.03 M undefined-175.31 M undefined
2024e8.49 M undefined-185.73 M undefined-186.02 M undefined
20232.13 M undefined-263.46 M undefined-246.42 M undefined
20221.07 M undefined-227.96 M undefined-221.1 M undefined
20210 undefined-165.32 M undefined-165.16 M undefined
20200 undefined-83.28 M undefined-81.36 M undefined
20190 undefined-44.5 M undefined-43.13 M undefined
20180 undefined-22.79 M undefined-22.71 M undefined
20170 undefined-11.15 M undefined-11.05 M undefined

IGM Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
00000128845224359555
------100.00300.00-462.50397.7860.2754.60
-------------
0000000000000
-11-22-44-83-165-227-263-185-241-243-133-410
------22,700.00-13,150.00-2,312.50-3,012.50-540.00-59.38-11.42-
-11-22-43-81-165-221-246-186-175-152-162-160-99
-100.0095.4588.37103.7033.9411.31-24.39-5.91-13.146.58-1.23-38.13
28.8928.8930.4930.7533.4841.5452.31000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The IGM Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IGM Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
0.41.9224.6366.3229.5427.2337.68
0000000
0000000
0000000
0.20.56.4711.211.39.92
0.62.4231373.3240.7438.5347.6
0.71.51834.856.373.174.01
00120000
0000000
0000000
0000000
0.10.10.30.5121.81
0.81.630.335.357.375.175.81
1.44261.3408.6298513.6423.41
             
40.860.90.30.30.30.40.59
0.0400.350.570.60.861.02
-41.4-64.1-107.2-188.6-353.7-574.8-821.24
-34.6-2.500000
0000-100-700151
0.3-4.9240.2381.7244.9287.3203.23
0.20.23.17.95.62.51.33
0.53.65.89.322.239.437.38
0.20.10002.73.78
0500000
0000000
0.98.98.917.227.844.642.48
0000000
0000000
0.1012.29.625.4181.6177.7
0.1012.29.625.4181.6177.7
18.921.126.853.2226.2220.18
1.34261.3408.5298.1513.5423.41
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IGM Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IGM Biosciences's financial health and stability.

Assets

IGM Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IGM Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IGM Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IGM Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-11-22-43-81-165-221-246
0001468
0000000
02-526155-6
00318559899
0000000
0000000
-10-20-45-67-124-5-192
00-2-17-13-10-12
00-2035815-22568
00-2007528-21580
0000000
05150000
8172692153218113
8222822142219115
00-2,000-1,000001,000
0000000
-2133205-107-12-8
-10.75-20.83-47.46-85.38-138.22-16.06-204.61
0000000

IGM Biosciences stock margins

The IGM Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IGM Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IGM Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IGM Biosciences's sales revenue. A higher gross margin percentage indicates that the IGM Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IGM Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IGM Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IGM Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IGM Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IGM Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IGM Biosciences Margin History

IGM Biosciences Gross marginIGM Biosciences Profit marginIGM Biosciences EBIT marginIGM Biosciences Profit margin
2029e0 %0 %-17.97 %
2028e0 %-11.66 %-44.79 %
2027e0 %-59.62 %-72.28 %
2026e0 %-535.19 %-335.98 %
2025e0 %-2,685.26 %-1,953.14 %
2024e0 %-2,187.88 %-2,191.35 %
20230 %-12,369.06 %-11,568.83 %
20220 %-21,304.67 %-20,663.55 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

IGM Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The IGM Biosciences earnings per share therefore indicates how much revenue IGM Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IGM Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IGM Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IGM Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IGM Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IGM Biosciences Revenue, EBIT and net profit per share

DateIGM Biosciences Sales per ShareIGM Biosciences EBIT per shareIGM Biosciences Earnings per Share
2029e9.36 undefined0 undefined-1.68 undefined
2028e6.06 undefined0 undefined-2.71 undefined
2027e3.78 undefined0 undefined-2.73 undefined
2026e0.77 undefined0 undefined-2.58 undefined
2025e0.15 undefined0 undefined-2.96 undefined
2024e0.14 undefined0 undefined-3.14 undefined
20230.04 undefined-5.04 undefined-4.71 undefined
20220.03 undefined-5.49 undefined-5.32 undefined
20210 undefined-4.94 undefined-4.93 undefined
20200 undefined-2.71 undefined-2.65 undefined
20190 undefined-1.46 undefined-1.41 undefined
20180 undefined-0.79 undefined-0.79 undefined
20170 undefined-0.39 undefined-0.38 undefined

IGM Biosciences business model

IGM Biosciences Inc was founded in 2010 in Mountain View, California. It is a biopharmaceutical company focused on the development and commercialization of immunotherapy products for the treatment of cancer. Their business model is based on the use of proprietary technology platform to produce high-quality and high-quantity antibody products. The company has different business areas including research and development, antibody production and testing, and marketing and distribution of their products. They offer a wide range of products such as monoclonal antibodies, multi-specific antibodies, and antibody constructs. Their history began with the development of their platform technology, which allows for the production of antibodies with modified properties. This has led to breakthrough products for the treatment of cancer. One of their main products is IGM-2323, a multi-specific antibody targeting solid tumors. It works by binding to two different targets on the cancer cell simultaneously and activating the immune system to destroy the cancer cell. Another important product is IGM-8444, an antibody construct targeting B-cell lymphomas. It has been designed to enhance the immune response to cancer cells by specifically binding to a surface protein on the cancer cells. IGM Biosciences Inc has also formed partnerships with other companies to collaborate on the development of new products. For example, they have partnered with GlaxoSmithKline (GSK) to develop a new class of multi-specific antibodies for the treatment of cancer. Overall, IGM Biosciences Inc has a strong track record and continues to have significant growth potential in the future. Their business model is based on leveraging their proprietary technology platform to develop innovative immunotherapy products for cancer. With a wide range of products and partnerships in the pipeline, it is likely that this company will continue to be successful in the future. IGM Biosciences is one of the most popular companies on Eulerpool.com.

IGM Biosciences SWOT Analysis

Strengths

IGM Biosciences Inc has a strong portfolio of proprietary IgM antibodies that offer unique advantages over traditional IgG-based therapies. These antibodies have the potential to provide improved efficacy and selectivity, and they may also have better safety profiles due to their larger size and less frequent dosing requirements.

The company's platform technology allows for the rapid development and optimization of these antibodies, enabling IGM Biosciences to quickly bring new and innovative therapies to market. This speed and flexibility give the company a competitive edge in the industry.

IGM Biosciences has established collaborations and partnerships with leading biopharmaceutical companies, which provides access to additional resources, expertise, and potential licensing opportunities. These partnerships contribute to the company's growth and market reach.

Weaknesses

One of the main weaknesses of IGM Biosciences is its current limited product pipeline. While the company has a promising portfolio of IgM antibodies, it may face challenges if its product development efforts do not yield successful candidates or encounter delays.

As a relatively small biotech company, IGM Biosciences may also have limited financial resources compared to larger competitors. This could impact its ability to fund research and development activities, as well as marketing efforts to bring its therapies to market.

Opportunities

The growing demand for novel and targeted therapies in the field of oncology presents a significant opportunity for IGM Biosciences. The company's unique IgM antibodies have the potential to address unmet medical needs and target specific cancer types more effectively, opening avenues for partnerships and commercial success.

IGM Biosciences can also explore opportunities for expanding its product pipeline through strategic collaborations or acquisitions. This would allow the company to diversify its offerings and access new technologies or research platforms.

Threats

The biopharmaceutical industry is highly competitive and subject to rapid technological advancements. IGM Biosciences may face intense competition from larger and more established companies that possess greater financial resources, broader product portfolios, and established relationships with key stakeholders such as healthcare providers and payers.

Additionally, regulatory and market access challenges can pose threats to IGM Biosciences. The approval process for new therapies can be rigorous and time-consuming, and securing reimbursement from insurance providers may also be a hurdle. These factors can impact the company's ability to generate revenue and achieve market success.

IGM Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IGM Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

IGM Biosciences shares outstanding

The number of shares was IGM Biosciences in 2023 — This indicates how many shares 52.312 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IGM Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IGM Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IGM Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IGM Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for IGM Biosciences.

IGM Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.04 -0.79  (-1,951.95 %)2024 Q2
3/31/2024-0.85 -0.83  (2.12 %)2024 Q1
12/31/2023-1.05 -1.01  (4.11 %)2023 Q4
9/30/2023-1.24 -1.04  (15.95 %)2023 Q3
6/30/2023-1.46 -1.43  (2.24 %)2023 Q2
3/31/2023-1.39 -1.33  (4.39 %)2023 Q1
12/31/2022-1.27 -1.19  (6.4 %)2022 Q4
9/30/2022-1.45 -1.32  (9.27 %)2022 Q3
6/30/2022-0.96 -1.33  (-38.72 %)2022 Q2
3/31/2022-1.65 -1.53  (7.05 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the IGM Biosciences stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

54

👫 Social

80

🏛️ Governance

26

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

IGM Biosciences shareholders

%
Name
Stocks
Change
Date
6.89534 % Baker Bros. Advisors LP4,090,316399,3053/29/2024
5.73789 % T. Rowe Price Associates, Inc.3,403,714281,8341/31/2024
5.22660 % Invus Public Equities Advisors, LLC3,100,422578,17812/31/2023
4.99125 % Redmile Group, LLC2,960,812-10,7303/29/2024
2.86329 % Fidelity Management & Research Company LLC1,698,506-438,46612/31/2023
17.53298 % Haldor Topsoe Holding A/S10,400,56406/30/2023
1.73473 % Goldman Sachs & Company, Inc.1,029,043591,94212/31/2023
1.58041 % RA Capital Management, LP937,500012/31/2023
1.51239 % The Vanguard Group, Inc.897,149-1,54912/31/2023
1.17001 % BlackRock Institutional Trust Company, N.A.694,047-75,05612/31/2023
1
2
3
4
5
...
10

IGM Biosciences Executives and Management Board

Mr. Fred Schwarzer71
IGM Biosciences President, Chief Executive Officer, Director (since 2003)
Compensation 5.32 M
Dr. Lisa Decker54
IGM Biosciences Chief Business Officer
Compensation 4.86 M
Dr. Bruce Keyt70
IGM Biosciences Chief Scientific Officer
Compensation 1.84 M
Mr. Chris Takimoto64
IGM Biosciences Chief Medical Officer
Compensation 1.83 M
Mr. Misbah Tahir48
IGM Biosciences Chief Financial Officer
Compensation 588,979
1
2
3

IGM Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AbCellera Biolog Stock
AbCellera Biolog
SupplierCustomer0,940,960,460,850,87-
BeiGene Stock
BeiGene
SupplierCustomer0,510,840,050,900,780,50
Atreca A Stock
Atreca A
SupplierCustomer-0,120,820,130,700,930,66
Avid Bioservices Stock
Avid Bioservices
SupplierCustomer-0,160,74-0,090,820,44-0,09
Medivir B Stock
Medivir B
SupplierCustomer-0,730,35-0,180,860,360,03
1

Most common questions regarding IGM Biosciences

What values and corporate philosophy does IGM Biosciences represent?

IGM Biosciences Inc represents values of innovation, integrity, and dedication in the field of biotechnology. With a strong emphasis on developing transformative and personalized therapies, IGM Biosciences Inc aims to improve the lives of patients suffering from serious diseases. The company's corporate philosophy revolves around scientific excellence, collaboration with experts, and a patient-centric approach. By leveraging its proprietary antibody engineering technology, IGM Biosciences Inc strives to create novel therapeutics that address significant unmet medical needs. Their commitment to advancing scientific research and delivering effective treatments underscores their mission to make a positive impact on global healthcare.

In which countries and regions is IGM Biosciences primarily present?

IGM Biosciences Inc is primarily present in the United States.

What significant milestones has the company IGM Biosciences achieved?

IGM Biosciences Inc has achieved several significant milestones. Notably, the company successfully completed its initial public offering in March 2020, raising approximately $175 million. Furthermore, IGM Biosciences has made substantial progress in advancing its pipeline of IgM antibody-based therapeutics. They have initiated clinical trials for their lead product candidate, IGM-2323, designed to treat patients with solid and hematologic malignancies. Additionally, the company has established strategic partnerships with renowned academic institutions and biopharmaceutical companies to further their research and development efforts. These achievements highlight IGM Biosciences' commitment to developing innovative therapies and advancing the field of immunoglobulin M (IgM) antibodies.

What is the history and background of the company IGM Biosciences?

IGM Biosciences Inc is a renowned biotechnology company based in Mountain View, California. Established in 2010, the company focuses on the development of innovative immunotherapies for the treatment of cancer and other diseases. With a strong emphasis on research and development, IGM Biosciences Inc utilizes its proprietary platform technology, called IgM antibody technology, to develop next-generation antibodies for targeted therapy. The company has successfully collaborated with various pharmaceutical and biotech companies to advance its therapeutic pipeline. IGM Biosciences Inc aims to revolutionize the field of immunotherapy with its cutting-edge scientific approach and commitment to improving patient outcomes.

Who are the main competitors of IGM Biosciences in the market?

The main competitors of IGM Biosciences Inc in the market include established biotechnology companies such as Amgen, Inc., Gilead Sciences, Inc., and Genentech. These companies have a strong presence in the biopharmaceutical industry and compete with IGM Biosciences in terms of developing novel antibody therapies, conducting clinical trials, and commercializing their products. By continually innovating and leveraging its unique antibody engineering platform, IGM Biosciences strives to differentiate itself from its competitors and address unmet medical needs.

In which industries is IGM Biosciences primarily active?

IGM Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of IGM Biosciences?

IGM Biosciences Inc is a biotechnology company that focuses on the development and discovery of engineered IgM antibodies for the treatment of various diseases. With its innovative business model, IGM Biosciences Inc aims to leverage its expertise in antibody engineering to bring novel treatments to patients. The company utilizes its proprietary IgM antibody technology platform to create next-generation therapeutics with enhanced therapeutic potential. IGM Biosciences Inc is committed to addressing unmet medical needs and advancing the field of antibody-based therapies through its research and development efforts.

What is the P/E ratio of IGM Biosciences 2024?

The IGM Biosciences P/E ratio is -4.08.

What is the P/S ratio of IGM Biosciences 2024?

The IGM Biosciences P/S ratio is 89.35.

What is the AlleAktien quality score of IGM Biosciences?

The AlleAktien quality score for IGM Biosciences is 3/10.

What is the revenue of IGM Biosciences 2024?

The expected IGM Biosciences revenue is 8.49 M USD.

How high is the profit of IGM Biosciences 2024?

The expected IGM Biosciences profit is -186.02 M USD.

What is the business model of IGM Biosciences

IGM Biosciences Inc. is a biotechnology company that develops innovative products for cancer immunotherapy. Its business model is based on researching, developing, and commercializing monoclonal antibodies targeted specifically at cancer cells. IGM Biosciences Inc. has developed an advanced antibody engineering process known as the Antibody Engineering Platform (ADAPTIR). This technology allows the company to develop antibodies that target cells more specifically and have a higher efficacy than conventional antibodies. IGM Biosciences Inc. works closely with its customers to develop customized antibodies tailored to their specific needs. The company also has its own product pipeline focused on developing antibodies for the treatment of various types of cancer. One of the key areas of IGM Biosciences Inc. is preclinical research and development. The company has an experienced team of scientists and researchers working on developing new antibodies and therapies. The company also invests significant resources in clinical research to ensure the safety and efficacy of its products. IGM Biosciences Inc. also offers a wide range of services, including antibody manufacturing, product formulation and testing, and bulk antibody delivery. The company works with a variety of customers, including pharmaceutical companies, biotechnology companies, and research institutions. Some of the products developed by IGM Biosciences Inc. include IGM-2323, an antibody targeted at CD20, a protein found on B cells. IGM-2323 has been developed for the treatment of non-Hodgkin lymphomas and other B-cell disorders. Another important product of IGM Biosciences Inc. is IGM-8444, an antibody that targets the death receptor 5 or DR5. DR5 is a protein that is overexpressed in many cancer cells, including those resistant to standard treatments. IGM-8444 has shown promising results in preclinical studies and could become an important component of cancer therapy in the future. IGM Biosciences Inc. is a company dedicated to developing customized antibodies to fight cancer. The company has a unique technology platform that allows it to develop highly specific and powerful antibodies. IGM Biosciences Inc. has an experienced team of scientists and researchers working on developing new antibodies and therapies to provide more effective treatment for cancer patients.

What is the IGM Biosciences dividend?

IGM Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does IGM Biosciences pay dividends?

The dividend cannot currently be calculated for IGM Biosciences or the company does not pay out a dividend.

What is the IGM Biosciences ISIN?

The ISIN of IGM Biosciences is US4495851085.

What is the IGM Biosciences WKN?

The WKN of IGM Biosciences is A2PPQK.

What is the IGM Biosciences ticker?

The ticker of IGM Biosciences is IGMS.

How much dividend does IGM Biosciences pay?

Over the past 12 months, IGM Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGM Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IGM Biosciences?

The current dividend yield of IGM Biosciences is .

When does IGM Biosciences pay dividends?

IGM Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGM Biosciences?

IGM Biosciences paid dividends every year for the past 0 years.

What is the dividend of IGM Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGM Biosciences located?

IGM Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGM Biosciences from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did IGM Biosciences pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of IGM Biosciences in the year 2023?

In the year 2023, IGM Biosciences distributed 0 USD as dividends.

In which currency does IGM Biosciences pay out the dividend?

The dividends of IGM Biosciences are distributed in USD.

All fundamentals about IGM Biosciences

Our stock analysis for IGM Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGM Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.